Australian medtech startup Oli has secured $6.5 million in fresh funding to improve maternal and fetal care. The Sydney-based company plans to use this money to push forward its smart monitoring technology for pregnancy and childbirth. The startup wants to help doctors spot danger signs much earlier and lower the risk of serious problems during labour.
The funding round marks an important step for the company as it moves closer to large clinical trials and future product launch. Investors believe Oli’s technology may help hospitals improve safety for both mothers and babies during one of the most critical moments in healthcare.
Oli Focuses on Pregnancy Safety
Oli builds wearable medical technology for women during labour. The company created a wireless monitoring system that tracks both maternal and fetal health in real time. The device uses biosensors and artificial intelligence to study signals from the body and warn doctors about possible complications before they become severe.
Current monitoring systems in many hospitals still depend on old methods. In many cases, doctors only react after a problem appears. Oli wants to change that model by giving medical teams earlier warning signs. The company believes faster action may save lives and reduce emergency cases during childbirth.
The startup says its system may help predict conditions such as postpartum haemorrhage, fetal distress, and stillbirth risk. Postpartum haemorrhage, also known as PPH, remains one of the leading causes of preventable maternal death around the world.
Strong Investor Support
The latest Series A3 round brought support from several major investors. Scale Investors joined the round along with Clare Ventures and the University of Sydney. Their support shows growing confidence in healthcare technology that focuses on women and babies.
Many investors now look for solutions that improve patient care while also reducing pressure on hospitals. Oli’s platform fits that goal because it gives doctors more information in less time. Early warning systems may help hospitals avoid costly emergencies and improve patient outcomes.
The fresh capital will help Oli move into its next growth stage. The company plans to complete large clinical studies across Australia and the United States. These trials will test the accuracy and reliability of the technology in real hospital settings.
Plans for Regulatory Approval
Oli also plans to use the funding for regulatory submissions in Australia and the United States. The company aims to secure approval from Australia’s Therapeutic Goods Administration, also known as the TGA, along with the US Food and Drug Administration, widely known as the FDA.
Medical devices must pass strict checks before hospitals can use them. Regulators study safety, performance, and reliability before approval. This process often takes years and requires detailed clinical evidence.
For Oli, these approvals represent a major milestone. Success may open the door to hospital partnerships, global expansion, and commercial launch. The company also plans to expand manufacturing operations inside Australia as it prepares for larger demand in the future.
A Startup Born From Personal Experience
Oli began after founder Dr Sarah McDonald faced a traumatic childbirth experience herself. That difficult moment inspired her to search for better ways to protect mothers during labour. The startup was first known as Baymatob before later changing its name to Oli.
Personal experiences often shape healthcare innovation because founders understand the real problems patients face. In this case, the company grew from a direct need for better monitoring and faster response during childbirth.
CEO Tara Croft says labour monitoring technology has changed very little over the last few decades. According to her, many systems still fail to provide predictive insights before a medical emergency develops. Oli wants to fill that gap through data analysis and smart software tools.
How the Technology Works
Oli’s wearable system uses a network of wireless biosensors placed on the patient’s body. These sensors collect important information about both mother and baby during labour. The platform then studies the data through artificial intelligence models.
The software searches for patterns linked to complications. If the system detects a possible risk, doctors receive alerts that may help them act sooner. Earlier treatment may lower harm for both mother and child.
Traditional monitoring tools usually focus on only one part of labour at a time. Oli’s platform aims to combine multiple signals into one connected system. This broader view may help doctors make faster and more accurate decisions.
The company says its technology may eventually analyse up to 15 different pregnancy and birth complications. That goal could make the platform one of the most advanced maternal monitoring systems in the sector.
Why Earlier Detection Matters
Childbirth complications can appear very quickly. In many cases, doctors have only a short window to respond before the situation becomes dangerous. Delays may increase the risk of severe injury or death.
Postpartum haemorrhage remains a major concern in hospitals worldwide. Heavy bleeding after birth can become life-threatening within minutes if doctors do not act fast. Oli says early studies suggest its platform may identify many PPH cases before bleeding even starts.
That early warning may give medical teams extra time to prepare treatment and reduce panic during emergencies. Faster decisions may also reduce the need for invasive procedures or emergency surgery.
Fetal distress also requires immediate attention because oxygen loss may harm the baby. Better prediction tools may help doctors decide when intervention becomes necessary.
Growing Interest in Femtech
Oli enters a healthcare market that continues to attract more global attention. Investors and medical experts now place greater focus on femtech, a sector that supports women’s health through technology and data.
For many years, women’s health received less investment compared to other medical fields. That trend has slowly changed as startups develop new tools for fertility, pregnancy, menopause, and maternal care.
The demand for better maternal healthcare remains strong across many countries. Hospitals continue to search for ways to improve safety while also reducing staff workload. Smart monitoring systems may become an important part of that future.
Oli’s progress also highlights Australia’s growing medtech sector. Australian startups continue to gain global attention for innovation in healthcare devices, software, and biotechnology.
What Comes Next for Oli
The company now enters an important phase as it prepares for broader clinical testing and future market entry. Large hospital trials will likely shape how quickly the technology reaches patients.
If the results remain positive, Oli may become a major name in maternal healthcare technology over the next few years. Success could also encourage more investment into solutions that focus on women’s health and childbirth safety.
For now, the $6.5 million funding round gives Oli the resources needed to continue development and move closer to commercial launch. The company hopes its technology will help doctors predict risks earlier, improve care quality, and protect more mothers and babies during childbirth.
Also Read – What Is Venture Capital?